Tesevatinib

781613-23-8

C24H25Cl2FN4O2

DMSO : >= 30 mg/mL (61.05 mM)

Protein Tyrosine Kinase/RTK; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Protein Tyrosine Kinase/RTK

Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC₅₀s of 0.3, 16, 1.5, 8.7, and 1.4 nM. IC50 & Target: IC50: 0.3 nM (EGFR), 16 nM (EGFR), 1.5 nM (EGFR), 8.7 nM (EGFR), 1.4 nM (EGFR)^[1] In Vitro: Tesevatinib (XL-647) potently inhibits the EGF/ErbB2, VEGF, and ephrin RTK families. Tesevatinib (XL-647) is a reversible and ATP competitive inhibitor. Tesevatinib (XL-647) was inactive against a panel of 10 tyrosine kinases (including the insulin and the insulin-like growth factor-1 receptor) and 55 serine-threonine kinases (including cyclin-dependent kinases, stress-activated protein kinases, and protein kinase C isoforms). Tesevatinib (XL-647) inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors a double mutation (L858R and T790M) in the EGFR gene. In A431 cells, Tesevatinib (XL-647) reduces cell viability with IC₅₀ values of 13 nM^[1]. In Vivo: Tesevatinib (XL-647) shows potent and long-lived inhibition of the WT EGFR in vivo. Tesevatinib (XL-647) substantially inhibits the growth of H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density^[1].